PHVS (Pharvaris NV) Change In Receivables: $-0.71 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHVS Pharvaris NV PHVS
22 GF Score
Price $35.14
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV Change In Receivables?

Pharvaris NV PHVS +3.19% 22 Change In Receivables is $-0.71 Mil as of Jun. 2026. GuruFocus rates PHVS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Pharvaris NV's change in receivables for the quarter that ended in Jun. 2026 was $-0.08 Mil. It means Pharvaris NV's Accounts Receivable increased by $0.08 Mil from Mar. 2026 to Jun. 2026 .

Pharvaris NV's change in receivables for the fiscal year that ended in Dec. 2025 was $-0.39 Mil. It means Pharvaris NV's Accounts Receivable increased by $0.39 Mil from Dec. 2024 to Dec. 2025 .

Pharvaris NV's Accounts Receivable for the quarter that ended in Jun. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Pharvaris NV's liquidation value for the three months ended in Jun. 2026 was $334.59 Mil.

Pharvaris NV  (NAS:PHVS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Pharvaris NV's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Pharvaris NV's accounts receivable are only considered to be worth 75% of book value:

Pharvaris NV's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=366.684-32.093+0.75 * 0+0.5 * 0
=334.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharvaris NV Change In Receivables Related Terms

Pharvaris NV Change In Receivables Historical Data

* Premium members only.

The historical data trend for Pharvaris NV's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharvaris NV Change In Receivables Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only -0.15 0.34 -0.05 -0.04 -0.39

Pharvaris NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.16 -0.46 -0.33 -0.08
PHVS
22GF Score
Pharvaris NV PHVS
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharvaris NV Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.71 Mil mean?
Pharvaris NV (PHVS) has a Change In Receivables of $-0.71 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Pharvaris NV and its competitors.
Is Pharvaris NV's Change In Receivables too high?
Pharvaris NV's current Change In Receivables is $-0.71 Mil. Overall, Pharvaris NV has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's Change In Receivables compare to NKTR and NRIX?
Pharvaris NV's Change In Receivables of $-0.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Pharvaris NV and its competitors. Pharvaris NV's current Change In Receivables is $-0.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (PHVS) has a current Change In Receivables of $-0.71 Mil. The current Change In Receivables is $-0.71 Mil. Pharvaris NV's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Pharvaris NV (PHVS), the current Change In Receivables is $-0.71 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharvaris NV Business Description

Other Exchanges 9EN:Germany
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
22GF Score

Get the complete analysis for PHVS

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.14
Price